BioCryst outlines $625M-$645M 2026 ORLADEYO revenue target as HAE pipeline advances
Source: SeekingAlpha
2026-02-26 15:09:35 ET
More on BioCryst Pharmaceuticals
- BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript
- BioCryst Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
- BioCryst: The $700 Million Pivot From Oral Convenience To Injectable
- BioCryst Pharmaceuticals GAAP EPS of $1.12 beats by $1.07, revenue of $406.55M beats by $255.23M
- BioCryst Pharmaceuticals Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
BioCryst outlines $625M–$645M 2026 ORLADEYO revenue target as HAE pipeline advances
BioCryst Pharmaceuticals Inc.
NASDAQ: BCRX
BCRX Trading
-1.71% G/L:
$8.325 Last:
1,409,572 Volume:
$8.40 Open:
BCRX Latest News
February 26, 2026 07:00:00 am
BioCryst Reports Full Year 2025 Financial Results and Provides Business Update
BCRX Stock Data
$1,391,931,498
199,991,369
0.01%
88
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
